Global Plasma Reagin Rapid (RPR) Test Market Growth (Status and Outlook) 2025-2031

The global Plasma Reagin Rapid (RPR) Test market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of % from 2025 to 2031.

The Rapid Plasma Reagin (RPR) test is a blood test used to screen for syphilis, a sexually transmitted infection (STI) caused by the bacterium Treponema pallidum. The RPR test is a non-treponemal test, meaning it does not directly detect the presence of the syphilis bacterium but instead detects antibodies produced by the body in response to the infection.

The global market for the Plasma Reagin Rapid (RPR) test was experiencing steady growth due to the increasing prevalence of sexually transmitted infections (STIs) and the rising awareness about the importance of early detection and treatment. The RPR test is a widely used screening tool for syphilis, one of the most common STIs globally. North America held a significant share in the global RPR test market, driven by a high prevalence of STIs and well-established healthcare infrastructure. The region's focus on preventive healthcare and routine STI testing contributed to market growth. Europe was another prominent market for RPR tests, with increasing awareness about STI testing and government initiatives to control syphilis transmission. The Asia-Pacific region witnessed rapid market growth due to the large population, rising awareness about STIs, and efforts to improve healthcare access in developing countries.

ReportPrime's newest research report, the “Plasma Reagin Rapid (RPR) Test Industry Forecast” looks at past sales and reviews total world Plasma Reagin Rapid (RPR) Test sales in 2024, providing a comprehensive analysis by region and market sector of projected Plasma Reagin Rapid (RPR) Test sales for 2025 through 2031. With Plasma Reagin Rapid (RPR) Test sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Plasma Reagin Rapid (RPR) Test industry.

This Insight Report provides a comprehensive analysis of the global Plasma Reagin Rapid (RPR) Test landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Plasma Reagin Rapid (RPR) Test portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Plasma Reagin Rapid (RPR) Test market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Plasma Reagin Rapid (RPR) Test and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity.

Segmentation by Type:

• Monoclonal Antibodies Test
• Immunofluorescence Test
• Fluorescent Treponemal Antibody Absorption Test
• T. Pallidum Hemagglutination Assay

Segmentation by Application:

• Hospitals
• Specialty Clinics
• Diagnostics Laboratories
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Company's coverage with companies listed:

• Cardinal Health
• Abbott
• BD
• Roche Holding
• Thermo Fisher Scientific
• Siemens
• SEKISUI Diagnostics
• Immunostics
• Novacyt
• Arlington Scientific
• Lorne Laboratories
• Meridian Bioscience
• Bio-Rad Laboratories
• Mediclone Biotech
• Newmarket Biomedical

Key Questions Addressed in this Report: